Abstracts tagged "Infection"

Abstract Number: 1365 • ACR Convergence 2022
Adverse Events Associated with Belimumab Use in Pediatric Patients: Review and Analyses of the FDA Adverse Event Reporting System Database
Ivone Kim, Debra Ryan, Carmen Cheng and Cindy Kortepeter, Food and Drug Administration, Silver Spring, MD
Background/Purpose: FDA approved belimumab, the first targeted biological treatment for SLE, in March 2011 for adults with active, seropositive SLE receiving standard therapy. The indicated…
Abstract Number: 1821 • ACR Convergence 2022
Colchicine and Other Gout Medications and the Risk of COVID-19 Infection, Hospitalization, and Subsequent Outcomes in People with Gout
Jasvinder singh¹, Timothy Bergquist², Vithal Madhira³ and Alfred Anzalone⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Sage Bionetworks, Seattle, WA, ³Palila Software, L.L.C., Reno, NV, ⁴University of Nebraska Medical Center, Ohama, NE
Background/Purpose: To examine whether the use of colchicine and other gout medications is associated with the risk of COVID-19 infection, hospitalization, and subsequent outcomes in…
Abstract Number: 0781 • ACR Convergence 2022
Rituximab Treated Patients with Hypogammaglobulinemia Are Less Likely to Seroconvert Following SARS-CoV-2 Vaccine Supplemental Dose
Daniel Magliulo¹, Vasileios Kyttaris¹ and Emily Rose², ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center, West Roxbury, MA
Background/Purpose: Rituximab (RTX) is a very effective treatment for autoimmune rheumatic diseases (AIRD). However, treatment increases risk of infections and impairs responses to vaccines. Prior…
Abstract Number: 1396 • ACR Convergence 2022
Risk of Hospitalized Infections in Older Elderly Rheumatoid Arthritis Patients Treated with Biological/Targeted Synthetic DMARDs: Evaluation Using Data from a Japanese Claims Database
Masayoshi Harigai¹, Takao Fujii², Ryoko Sakai³, Ataru Igarashi⁴, Ayako Shoji⁵, Hiroko Yamaguchi⁶, Katsuhiko Iwasaki⁶, Misako Makishima⁷, Amika Yoshida⁷, Norihiro Okada⁷, Katsuhisa Yamashita⁷ and Yutaka Kawahito⁸, ¹Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ²Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan, ³Department of Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, Japan, ⁴Department of Health Economics & Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan; Unit of Public Health and Preventive Medicine, Yokohama City University of Medicine, Kanagawa, Japan, ⁵Medilead Inc., Tokyo, Japan; Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan; Healthcare Consulting Inc., Tokyo, Japan, Shinjuku-ku, Japan, ⁶Medilead Inc., Tokyo, Japan, Shinjuku-ku, Japan, ⁷Chugai Pharmaceutical Co., Ltd., Chuo-ku, Tokyo, Japan, ⁸Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, Kyoto, Kyoto, Japan
Background/Purpose: Safety evidence of biological or targeted synthetic DMARDs (b/tsDMARDs) is still insufficient in older elderly ( >=75 years old (y/o)) patients with rheumatoid arthritis…
Abstract Number: 1864 • ACR Convergence 2022
Hepatitis B Exposure and Infection in Idiopathic Inflammatory Myopathies: Prevalence, Presentation, and Treatment Response
Ana Valle¹, Xianhong Xie² and Shereen Mahmood³, ¹Montefiore Medical Center, New York, NY, ²Department of Epidemiology & Population Health/Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY
Background/Purpose: Hepatitis B (HBV) screening in patients with autoimmune conditions is vital prior to the initiation of immunosuppressive therapy given the risk of HBV reactivation.…
Abstract Number: 0120 • ACR Convergence 2022
Epstein Barr Virus Reactivation in Native American Rheumatic Disease Patients Is Associated with Systemic Disease and Rheumatoid Arthritis but Not Other Rheumatic Diseases
Carla J. Guthridge¹, Catriona Wagner², Sohail Khan³, Michael Peercy⁴, Bobby Saunkeah⁴, Joel Guthridge¹ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Santa Cruz, CA, ³Cherokee Nation, Tahlequah, OK, ⁴Chickasaw Nation, Ada, OK
Background/Purpose: EBV infection is associated with autoantibody development in the preclinical period of rheumatic diseases, such as SLE and RA. Furthermore, EBV reactivation, characterized by…
Abstract Number: 0784 • ACR Convergence 2022
Breakthrough SARS-CoV-2 Infections in Immune Mediated Disease Patients Undergoing B Cell Depleting Therapy: A Retrospective Cohort Analysis
Cassandra Calabrese¹, Elizabeth Kirchner², M. Elaine Husni³, Brandon Moss², Anthony Fernandez², Yuxuan Jin³ and Leonard Calabrese³, ¹Cleveland Clinic Foundation, Cleveland Heights, OH, ²Cleveland Clinic Foundation, Cleveland, OH, ³Cleveland Clinic, Cleveland, OH
Background/Purpose: Immunocompromised patients with immune mediated inflammatory diseases (IMIDs) undergoing therapy with B cell depleting agents (BCDT) are among the most vulnerable to severe COVID-19…
Abstract Number: 1403 • ACR Convergence 2022
Herpes Zoster in Rheumatoid Arthritis: Prospective Single University Center Study
Lucia Cristina Dominguez Casas¹, Mª Paz Rodriguez Cundin², Trinidad Dierssen Sotos³, Nuria Vegas Revenga⁴, Alfonso Corrales⁵, Miguel Ángel González-Gay⁶ and Ricardo Blanco⁷, ¹Hospital Universtario San Agustin, Oviedo, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Universidad de Cantabria, Santander, Spain, ⁴Hospital Galdakao- Usansolo, Galdakao, Spain, ⁵Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁷Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Patients with Rheumatoid arthritis (RA) have an increased risk of infections due to the disease itself, and/or immunosuppressive therapy. The risk of herpes zoster…
Abstract Number: 1950 • ACR Convergence 2022
Morbidities Associated with Serious Infections in Patients with Rheumatoid Arthritis
Bradly Kimbrough¹, Cynthia Crowson², Ryan Lennon³, John Davis³ and Elena Myasoedova³, ¹Mayo Clinic Rochester, Rochester, MN, ²Mayo Clinic, Eyota, MN, ³Mayo Clinic, Rochester, MN
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk for serious infections. Several infection risk scores have been developed over the last decade for…
Abstract Number: 0151 • ACR Convergence 2022
Novel Innate Immunity Predictors of Infections in Idiopathic Inflammatory Myopathies Patients: A Cohort Study
Diana Gómez-Martín¹, jiram torres-Ruiz¹, victor Hugo Tovar-Méndez², Fabiola Cassiano-Quezada³, Daniel Alberto Carrillo-Vázquez⁴, Alfredo Pérez-Fragoso⁴, Nancy Mejía-Rodríguez⁵ and guillermo Juárez-Vega⁵, ¹INCMNSZ, Ciudad de México, Mexico, ²Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ⁴Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ⁵Red de Apoyo a la Investigación. UNAM, Ciudad de México, Mexico
Background/Purpose: Risk factors associated with the development of infections in patients with idiopathic inflammatory myopathies (IIM) have not been fully addressed, particularly those related to…
Abstract Number: 0785 • ACR Convergence 2022
Humoral Immune Responses Following Four SARS-CoV-2 Vaccine Doses or COVID-19 Infection in Patients with Immune-Mediated Inflammatory Diseases on Immunosuppressive Therapy: A Prospective Cohort Study
Hilde Ørbo¹, Kristin Hammersbøen Bjørlykke², Joe Sexton¹, Anne Therese Tveter¹, Ingrid Jyssum¹, Ingrid Egeland Christensen¹, David Warren³, Tore K. Kvien¹, Adity Chopra⁴, Grete Birkeland Kro³, Jørgen Jahnsen², Ludvig A. Munthe³, Espen Haavardsholm¹, Gunnveig Grødeland³, Sella Aarrestad Provan¹, Kristin Kaasen Jørgensen², Silje Watterdal Syversen¹ and Guro Løvik Goll¹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Akershus University Hospital, Oslo, Norway, ³Oslo University Hospital, Oslo, Norway, ⁴Oslo University Hospital, Oslo, Oslo, Norway
Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapy have impaired humoral immune responses to SARS-CoV-2 vaccination. This study aimed to assess serologic response…
Abstract Number: 1422 • ACR Convergence 2022
Incidence and Determinants of Infection in Rheumatoid Arthritis (RA) Patients (Pts) Treated with Subcutaneous Golimumab (GLM) in Canadian Real-World Practice
Louis Bessette¹, Proton Rahman², John Kelsall³, Jane Purvis⁴, Emmanouil Rampakakis⁵, Allen J. Lehman⁶, Meagan Rachich⁷, Francois Nantel⁸, A. Marilise Marrache⁹ and Odalis Asin-Milan¹⁰, ¹Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ²Memorial University, St. John's, NL, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴Peterborough Education, Peterborough, ON, Canada, ⁵McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁶Janssen Inc., Toronto, ON, Canada, ⁷Janssen Inc., Guelph, ON, Canada, ⁸Nantel MedSci Consult, Montréal, QC, Canada, ⁹Janssen Inc., Dollard-des-Ormeaux, QC, Canada, ¹⁰Janssen Canada, Laval, QC, Canada
Background/Purpose: Although biologic use in RA has a well-characterized infections risk factor, most studies were done on 1st-generation anti-tumor necrosis factor (TNFi) drugs or post-drug…
Abstract Number: 1958 • ACR Convergence 2022
The Increased Risk of Staphylococcus Aureus Bacteremia in Rheumatoid Arthritis – What Is the Impact of Glucocorticoids, Biologic Disease-Modifying Anti-Rheumatic Drugs and Disease Activity: A Danish Nationwide Nested Case-Control Study in the DANBIO Registry
Sabine Dieperink¹, Bente Glintborg², Frank Mehnert³, Mette Nørgaard³, Louise Bruun Oestergaard⁴, Thomas Benfield⁵, Christian Torp-Pedersen⁶, Andreas Petersen⁷ and Merete Lund Hetland¹, ¹Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark, ²Rigshospitalet, Glostrup, Virum, Denmark, ³Aarhus University Hospital, Aarhus, Denmark, ⁴Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark, ⁵Copenhagen University Hospital - Amager and Hvidovre, Copenhagen, Denmark, ⁶Copenhagen University Hospital - North Zealand, Copenhagen, Denmark, ⁷Statens Serum Institut, Copenhagen, Denmark
Background/Purpose: Staphylococcus aureus bacteremia (SAB) has high mortality.[1] We have previously identified an approximately doubled risk in patients with rheumatoid arthritis (RA),[2] but the role…
Abstract Number: 0177 • ACR Convergence 2022
COVID-19 Vaccination-related Short-term Adverse Events in Patients with Idiopathic Inflammatory Myositis and Autoimmune Multimorbidity: Results from the COVID-19 Vaccination in Autoimmune Diseases Survey
Mrinalini Dey¹, Naveen R², Elena Nikiphorou³, Parikshit Sen⁴, James B. Lilleker⁵, Vishwesh Agarwal⁶, Sinan Kardes⁷, Jessica Day⁸, Marcin Milchert⁹, Mrudula Joshi¹⁰, Tamer A Gheita¹¹, Babur Salim¹², Tsvetelina Velikova¹³, Abraham Edgar Gracia-Ramos¹⁴, Ioannis Parodis¹⁵, Albert Selva O’Callaghan¹⁶, Minchul Kim¹⁷, Tulika Chatterjee¹⁷, Ai Lyn Tan¹⁸, Ashima Makol¹⁹, Arvind Nune²⁰, Lorenzo Cavagna²¹, Miguel Angel Saavedra Salinas²², Samuel Shinjo²³, Nelly Ziade²⁴, Johannes Knitza²⁵, Masataka Kuwana²⁶, Oliver Distler²⁷, Hector Chinoy²⁸, John Pauling²⁹, Chris Wincup³⁰, Vikas Agarwal², Rohit Aggarwal³¹ and Latika Gupta³², ¹Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³Leiden University Medical Center & King's College London, London, United Kingdom, ⁴Maulana Azad Medical College, New Delhi, India, ⁵The University of Manchester, Manchester, United Kingdom, ⁶Mahatma Gandhi Missions Medical College, Lucknow, India, ⁷Istanbul University, Istanbul, Turkey, ⁸Walter and Eliza Hall Institute, Melbourne, Australia, ⁹Pomeranian Medical University in Szczecin, Szczecin, Poland, ¹⁰Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India, ¹¹Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, ¹²Fauji foundation hospital Rawalpindi, Rawalpindi, Pakistan, ¹³Sofia University St. Kliment Ohridski, Sofia, Bulgaria, ¹⁴Instituto Mexicano del Seguro Social, Ciudad de México, Mexico, ¹⁵Karolinska Institutet, Stockholm, Sweden, ¹⁶Hospital Universitari Vall d'Hebron, Barcelona, Spain, ¹⁷University of Illinois College of Medicine Peoria, Peoria, IL, ¹⁸University of Leeds, Leeds, United Kingdom, ¹⁹Mayo Clinic, Rochester, MN, Rochester, MN, ²⁰Southport and Ormskirk Hospital NHS Trust, Southport, United Kingdom, ²¹Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Pavia, Italy, ²²IMSS, Ciudad de México, Mexico, ²³Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, Brazil, ²⁴Saint-Joseph University, Beirut, Lebanon, ²⁵Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ²⁶Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ²⁸The University of Manchester, Sale, United Kingdom, ²⁹North Bristol NHS Trust, Bristol, United Kingdom, ³⁰Rayne Institute, University College London, London, United Kingdom, ³¹Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ³²Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom
Background/Purpose: COVID-19 vaccines are safe and effective, though patients with rare rheumatic diseases like idiopathic inflammatory myositis (IIMs), and those with multiple comorbidities continue to…
Abstract Number: 0798 • ACR Convergence 2022
Uncovering the Relationship Between COVID-19 Outcome Severity and Rheumatic Disease
Natalie Allcott¹, Neha Gupta¹, Namita Raghavan¹, Huzaefah Syed² and Stamatina Danielides³, ¹VCU, Richmond, VA, ²Virginia Commonwealth University Medical Center, Richmond, VA, ³Virginia Commonwealth University Health System, Glen Allen, VA
Background/Purpose: The COVID-19 pandemic has caused great concern amongst immunocompromised patients, especially those with rheumatic diagnoses. While much has been learned in the past two…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].